Current Infectious Disease Reports

, Volume 14, Issue 1, pp 1–8

Cholera: Lessons from Haiti and Beyond

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (DA Bobak, Section Editor)

Abstract

Cholera is an acute, severe diarrheal disease caused by Vibrio cholerae that affects millions of people each year. Without prompt rehydration, death can occur within hours of the onset of symptoms. In October 2010, cholera emerged in Haiti, and the resulting large epidemic continues today. As of August 29, 2011, more than 439,000 cases have been reported in Haiti, with over 6,200 deaths. This review covers important features of epidemiology, pathogenesis, treatment and prevention of cholera, with a focus on the ongoing epidemic in Haiti.

Keywords

Cholera Endemic Epidemic Vibrio cholerae Cholera toxin Oral rehydration solution Herd immunity Case fatality rate 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Cholera--Peru, 1991. MMWR Morb Mortal Wkly Rep. 1991;40(6):108–10.Google Scholar
  2. 2.
    Kaper JB, Morris Jr JG, Levine MM. Cholera. Clin Microbiol Rev. 1995;8(1):48–86.PubMedGoogle Scholar
  3. 3.
    Faruque SM, Ahmed KM, Siddique AK, et al. Molecular analysis of toxigenic Vibrio cholerae O139 Bengal strains isolated in Bangladesh between 1993 and 1996: evidence for emergence of a new clone of the Bengal vibrios. J Clin Microbiol. 1997;35(9):2299–306.PubMedGoogle Scholar
  4. 4.
    • Mutreja A, Kim DW, Thomson NR, et al.: Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011;477(7365):462–5. Authors present evidence for the spread of global cholera in independent waves during the last six decades, and illustrate the influence of antibiotic resistance genes on the spread of the seventh pandemic. Google Scholar
  5. 5.
    Siddique AK, Nair GB, Alam M, et al.: El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect. 2009;138(3):347–52.Google Scholar
  6. 6.
    Nair GB, Qadri F, Holmgren J, et al. Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol. 2006;44(11):4211–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis. 2007;7(8):521–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Sack DA, Sack RB, Chaignat CL. Getting serious about cholera. N Engl J Med. 2006;355(7):649–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Glass RI, Becker S, Huq MI, et al. Endemic cholera in rural Bangladesh, 1966–1980. Am J Epidemiol. 1982;116(6):959–70.PubMedGoogle Scholar
  10. 10.
    Bompangue D, Giraudoux P, Piarroux M, et al. Cholera epidemics, war and disasters around Goma and Lake Kivu: an eight-year survey. PLoS Negl Trop Dis. 2009;3(5):e436.PubMedCrossRefGoogle Scholar
  11. 11.
    Gaffga NH, Tauxe RV, Mintz ED. Cholera: a new homeland in Africa? Am J Trop Med Hyg. 2007;77(4):705–13.PubMedGoogle Scholar
  12. 12.
    Griffith DC, Kelly-Hope LA, Miller MA. Review of reported cholera outbreaks worldwide, 1995–2005. Am J Trop Med Hyg. 2006;75(5):973–7.PubMedGoogle Scholar
  13. 13.
    Floret N, Viel JF, Mauny F, et al. Negligible risk for epidemics after geophysical disasters. Emerg Infect Dis. 2006;12(4):543–8.PubMedGoogle Scholar
  14. 14.
    Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988;2(8609):467–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ. 1967;36(6):871–83.PubMedGoogle Scholar
  16. 16.
    Hartley DM, Morris Jr JG. Smith DL: Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS Med. 2006;3(1):e7.PubMedCrossRefGoogle Scholar
  17. 17.
    Weil AA, Khan AI, Chowdhury F, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49(10):1473–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Harris JB, Larocque RC, Chowdhury F, et al. Susceptibility to Vibrio cholerae Infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis. 2008;2(4):e221.PubMedCrossRefGoogle Scholar
  19. 19.
    Sack DA, Tacket CO, Cohen MB, et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun. 1998;66(5):1968–72.PubMedGoogle Scholar
  20. 20.
    Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun. 2005;73(11):7422–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Larocque RC, Sabeti P, Duggal P, et al. A variant in long palate, lung and nasal epithelium clone 1 is associated with cholera in a Bangladeshi population. Genes Immun. 2009;10(3):267–72.PubMedCrossRefGoogle Scholar
  22. 22.
    von Seidlein L, Wang XY, Macuamule A, et al. Is HIV infection associated with an increased risk for cholera? Findings from a case–control study in Mozambique. Trop Med Int Health. 2008;13(5):683–8.CrossRefGoogle Scholar
  23. 23.
    Rey JL, Milleliri JM, Soares JL, et al. HIV seropositivity and cholera in refugee children from Rwanda. Aids. 1995;9(10):1203–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Gill DM, Meren R. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci U S A. 1978;75(7):3050–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Ryan ET, Dhar U, Khan WA, et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg. 2000;63(1–2):12–20.PubMedGoogle Scholar
  26. 26.
    Harris JR, Cavallaro EC, de Nobrega AA, et al. Field evaluation of crystal VC rapid dipstick test for cholera during a cholera outbreak in Guinea-Bissau. Trop Med Int Health. 2009;14(9):1117–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Cholera outbreak. Assessing the outbreak response and improving preparedness. World Health Organization http://whqlibdocwhoint/hq/2004/WHO_CDS_CPE_ZFk_20044_engpdf. 2004.
  28. 28.
    Water with sugar and salt. Lancet. 1978;2(8084):300–1.Google Scholar
  29. 29.
    Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354(23):2452–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Garriss G, Waldor MK, Burrus V. Mobile antibiotic resistance encoding elements promote their own diversity. PLoS Genet. 2009;5(12):e1000775.PubMedCrossRefGoogle Scholar
  31. 31.
    Khan WA, Saha D, Rahman A, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet. 2002;360(9347):1722–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics. 2007;119(6):1120–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Roy SK, Hossain MJ, Khatun W, et al. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ. 2008;336(7638):266–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Francis DK: Vitamin a supplementation for preventing death and illness in children 6 months to 5 years of age. Cochrane Database Syst Rev. 2011(8):ED000016.Google Scholar
  35. 35.
    Chowdhury F, Khan AI, Faruque AS, Ryan ET. Severe, acute watery diarrhea in an adult. PLoS Negl Trop Dis. 2010;4(11):e898.PubMedCrossRefGoogle Scholar
  36. 36.
    Treatment of the patient with cholera. World Health Organization. 2011;Emerging and other Communicable Diseases, Surveillance and Control. http://www.who.int/csr/resources/publications/cholera/whocddser9115rev1.pdf.
  37. 37.
    Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990;335(8684):270–3.PubMedCrossRefGoogle Scholar
  38. 38.
    • Ali M, Emch M, von Seidlein L, et al.: Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005;366(9479):44–9. This re-analysis of a whole-cell killed cholera vaccine placebo-controlled trial in Bangladesh integrates estimates of herd protection into the vaccine efficacy results, demonstrating a significant increase in protection. Google Scholar
  39. 39.
    • Sur D, Lopez AL, Kanungo S, et al.: Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9702):1694–702. These encouraging preliminary results describe protection from cholera in adults and children using an inexpensive and safe WHO-approved oral vaccine candidate. Google Scholar
  40. 40.
    Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile–a new humanitarian and diplomatic resource. N Engl J Med. 2011;363(24):2279–82.CrossRefGoogle Scholar
  41. 41.
    Update: cholera outbreak—Haiti, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(45):1473–9.Google Scholar
  42. 42.
    Informations sur le cholera. Rapport du 10 juillet mai 2011. Ministere de la Sante Publique et de la Population. 2011;http://www.mspp.gouv.ht/site/index.php?option=com_content&view=article&id=57&Itemid=1.
  43. 43.
    Progress on sanitation and drinking water. World Health Organization and UNICEF. Geneva, Switzerland. 2010;http://www.who.int/water_sanitation_health/publications/9789241563956/en/index.html.(Accessed June 1, 2011).
  44. 44.
    • Ivers LC, Farmer P, Almazor CP, Leandre F: Five complementary interventions to slow cholera: Haiti. Lancet. 2010;376(9758):2048–51. Discussion of the most important interventions for Haiti’s epidemic, including improved treatment of cholera patients, acquisition of cholera vaccines, clean water provision, strengthening of Haiti’s health care system, and an integrated, united approach to cholera care and prevention programs. Google Scholar
  45. 45.
    Farmer P, Almazor CP, Bahnsen ET, et al. Meeting cholera’s challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis. 2011;5(5):e1145.PubMedCrossRefGoogle Scholar
  46. 46.
    Hendriksen RS, Price LB, Schupp JM, et al. Population genetics of Vibrio cholerae from Nepal in 2010: evidence on the origin of the Haitian outbreak. MBio. 2011;2(4):e00157–11.PubMedCrossRefGoogle Scholar
  47. 47.
    • Chin CS, Sorenson J, Harris JB, et al.: The origin of the Haitian cholera outbreak strain. N Engl J Med. 2011;364(1):33–42. Using third generation DNA sequencing techniques, authors determine that the V. cholerae strain found in Haiti is most closely related to South Asian strains. Google Scholar
  48. 48.
    World Health Organization. Meeting the MDG drinking water and sanitation target. The urban and rural challenge of the decade. http://wwwwhoint/water_sanitation_health/monitoring/jmpfinalpdf Accessed October 9th, 2011.
  49. 49.
    Chambers K. Zimbabwe's battle against cholera. Lancet. 2009;373(9668):993–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Siddique AK, Salam A, Islam MS, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet. 1995;345(8946):359–61.PubMedCrossRefGoogle Scholar
  51. 51.
    World Health Organization Global Task Force on Cholera Control Prevention and Control of cholera outbreaks; WHO policy and recommendations. http://wwwwhoint/cholera/technical/prevention/control/en/index2html Accessed Oct 9, 2011.
  52. 52.
    Gupta SPG, Sircar BK, Mondal S, et al. Effect of doxycycline on transmission of Vibrio cholerae infection among family contacts of cholera patients in Calcutta. Bull World Health Organ. 1978;56(2):323–6.PubMedGoogle Scholar
  53. 53.
    Deb BC, Sen Gupta PG, De SP, et al. Effect of sulfadoxine on transmission of Vibrio cholerae infection among family contacts of cholera patients in Calcutta. Bull World Health Organ. 1976;54(2):171–5.PubMedGoogle Scholar
  54. 54.
    McCormack WM, Chowdhury AM, Jahangir N, et al. Tetracycline prophylaxis in families of cholera patients. Bull World Health Organ. 1968;38(5):787–92.PubMedGoogle Scholar
  55. 55.
    Larson CP, Saha UR, Islam R, Roy N. Childhood diarrhoea management practices in Bangladesh: private sector dominance and continued inequities in care. Int J Epidemiol. 2006;35(6):1430–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Chowdhury AK, Matin MA, Islam MA, Khan OF. Prescribing pattern in acute diarrhoea in three districts in Bangladesh. Trop Doct. 1993;23(4):165–6.PubMedGoogle Scholar
  57. 57.
    • Cholera vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(13):117–28. In response to accumulating results of cholera vaccine trials showing safety and efficacy of oral cholera vaccines, the WHO recommends consideration of vaccines in addition to other control measures during epidemics and potential epidemics. Google Scholar
  58. 58.
    • Thiem VD, Deen JL, von Seidlein L, et al.: Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine. 2006;24(20):4297–303. Authors describe a case–control analysis of WC vaccine efficacy during a cholera outbreak that occurred several years after initial vaccination of individuals in Hue, Vietnam. Google Scholar
  59. 59.
    • Reyburn R, Deen JL, Grais RF, et al.: The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5(1):e952. Authors describe several models for treatment of past cholera outbreaks and predict the disease averted by use of existing vaccine. Google Scholar
  60. 60.
    • Andrews JR, Basu S: Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet. 2011. This study describes a model of the epidemic in Haiti and the subsequent decrease in cases that may occur with the use of vaccination, enhanced antibiotic distribution, and provision of clean water. Google Scholar
  61. 61.
    • Jeuland M, Cook J, Poulos C, et al.: Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009;12(6):899–908. Authors re-estimate cost-effectiveness analyses for oral cholera vaccine including the indirect effects of herd immunity, and find that these vaccines cross the threshold used for cost-effectiveness acceptance in typical vaccine programs. Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ana A. Weil
    • 1
  • Louise C. Ivers
    • 2
    • 3
  • Jason B. Harris
    • 4
    • 5
  1. 1.Department of Medicine, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Division of Global Health EquityBrigham and Women’s HospitalBostonUSA
  3. 3.Department of Global HealthHarvard Medical SchoolBostonUSA
  4. 4.Division of Infectious DiseasesMassachusetts General HospitalBostonUSA
  5. 5.Department of PediatricsHarvard Medical SchoolBostonUSA

Personalised recommendations